GMAB (Genmab AS) Bathi saben saham sajrone patang kuartal pungkasan

Genmab A/S maximizes the delegation of production and testing to external contractors, focusing instead on antibody development. This daily price action of the rolling EPS YoY change displayed on GURU.Markets demonstrates business inertia, where -50.60 serves as the current metric level. High-yield targeted drugs drive revolutionary growth, while inelastic demand for oncology therapies guarantees stable cash flows through royalties.

GMAB Bathi saben saham sajrone rolas wulan pungkasan genmab.com (11.02.2024 - 12.11.2026)

Genmab US - rincian analitis lan metrik utama (GMAB)

- rega saiki lan proyeksi nilai saham:

Bagan owah-owahan rega genmab.com|GMAB - Target konsensus

- indikator valuasi pasar bisnis:

Nilai pasar Genmab AS|GMAB - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Genmab|GMAB - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku genmab.com|GMAB - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi lan kelipatan valuasi:

GMAB - Penghasilan resik|Penghasilan resik sing dikarepake Genmab A/S|GMAB - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Genmab AS|GMAB - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Genmab AS|GMAB - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Genmab|GMAB - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan genmab.com|GMAB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Genmab A/S

Pambiji fundamental:genmab.com (GMAB)

Genmab A/S minimizes capital expenditures by outsourcing production and clinical trials to third-party contractors. Analyzing the trailing twelve months (TTM) net income per share growth rate allows for an assessment of the efficiency of this asset-light business model. This metric measures profit dynamics over the last 12 months, revealing the actual pace of business scaling. It is critical for investors to monitor any deceleration in this growth to timely recognize the risk of asset overvaluation.

Analisis pesaing Genmab A/S